NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Alphabet-C
GOOG
US Stock MarketDetailed Quotes
IMRX Immuneering
- 2.000
- +0.160+8.70%
Close Dec 20 16:00 ET
- 1.950
- -0.050-2.50%
Post 17:51 ET
62.10MMarket Cap-1.02P/E (TTM)
2.080High1.790Low680.05KVolume1.790Open1.840Pre Close1.34MTurnover3.04%Turnover RatioLossP/E (Static)31.05MShares7.92052wk High1.08P/B44.78MFloat Cap1.00052wk Low--Dividend TTM22.39MShs Float33.990Historical High--Div YieldTTM15.76%Amplitude1.000Historical Low1.964Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Immuneering Stock Forum
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board. The advisory board, which comprises world-renowned oncology clinical researchers, will provide strategic medical and cli...
Immuneering Launches Pancreatic Cancer Advisory Board
Thursday, 19th December at 8:00 am
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer -
- Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 -
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company seeking t...
*************************************
REVERSE...
Immuneering Granted FDA Fast Track Designation for Imm-1-104 in Advanced Melanoma
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Thursday, 12th December at 8:00 am
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors -
- IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma -
- Melanoma patients actively enrolling in one of five arms in the co...
27/11/2024 - 22:00
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Pa...
No comment yet